Low molecular weight heparin: Pharmacoeconomics

Current Surgery

Volumn 53, Issue 4, 1996, Pages 225-230

  Ninno, Mark A ^a  

^a PITT COUNTY MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344635958     PISSN: 01497944     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Claggett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;106(suppl): 312S-333S.
2. Glazier RL, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976;236:1365-1367.
3. Salzman EW, Deykin D, Shapiro RM, Rosenberg R. Management of heparin therapy: controlled, prospective trial. N Engl J Med 1975; 292:1046-1050.
4. Hull R, Delmore T, Carter C, Hirsch J, Genton E, Gent M, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306: 189-194.
5. Hull R, Delmore T, Genton E, Hirsch J, Gent M, Sackett D, et al. Warfarin sodium versus low dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;301:855-858.
6. Anderson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sonderstrom G. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976;9:575.
7. Johnson EA, Kirkwood TB, Stiriling Y, Perez-Requejo JL. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976;35:586.
8. Lovenox® Product Information, Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, February 1995.
9. Fragmin® Product Information, Pharmacia Inc., Columbus, OH, May 1995.
10. Turpie, AGG, Levine MN, Hirsch J, Carter CJ, Jay RM, Powers PJ, et al. A randomized controlled trial of low molecular weight heparin (enoxaparin) to prevent deep vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315:925.
11. Leclerc J, Desjardins L, Geerts W, Jobin F, Delorme F, Bourgouin J. A randomized trial of enoxaparin for the prevention of deep vein thrombosis after major knee surgery. Thromb Haemost 1991; 65(suppl):753.
12. Hoek J, Nurmohamed MT, ten Cate H, ten Cate JW, Buller H. Prevention of deep vein thrombosis following total hip replacement by a low molecular weight heparin. Thromb Haemost 1989; 62(suppl):1637.
13. Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A, et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988;60:407.
14. Dechavanne M, Ville D, Berruyer M, Treyo F, Dalery B, Clersuone N, et al. Randomized trial of low molecular weight heparin (Kabi 2165) versus adjusted dose subcutaneous standard heparin in the prophylaxis of deep vein thrombosis after elective hip surgery. Haemostasis 1989;1:5.
15. Leyvraz PF, Bachmann F, Hoek J, Buller HR, Postel M, Samama M, et al. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin. Br Med J 1991;303:543.
16. Estoppey D, Hochreiter J, Breyer HG, Jakubek H, Leyvraz PF, Haas S, et al. ORG 10172 (lomoparin) versus heparin-DHE in prevention of thromboembolism in total hip replacement-a mullicenter trial. Thromb Haemost 1989;62(suppl):356.
17. The Danish Enoxaparin Study Group. Low-molecular weight heparin (enoxaparin) vs dextran 70: the prevention of postoperative deep vein thrombosis after total hip replacement. Arch Intern Med 1991;151:1621.
18. Bergqvist D, Kettunen K, Fredin H, Fauno P, Suomalainen S, Soimakallio S, et al. Thromboprophylaxis in hip fracture patients-a prospective randomized comparative study between ORG 10172 and dextran. Surgery 1991;109:617.
19. Erdman SM, Rodvold KA, Friedenberg WR. Thromboembolic disorders. In: DiPiro JT, Talbert RL, Hayes PE, Yee GC, Matzke GR, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. New York: Elsevier, 1992.
20. Green D, Hirsch J, Heit J, Prins M, Davidson B, Lensing AW. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994;46(1):89-109.
21. Tapson VF, Hull RD. Management of venous thromboembolic disease: the impact of low molecular weight heparin. Clin Chest Med 1995;16(2):281-294.
22. Barrowcliffe TW. Low molecular weight heparin(s). Br J Haematol 1995;90:1-7.
23. Wolf H. Low-molecular weight heparin. Med Clin N Am 1994; 78(3):733-743.
24. Young E, Prins MH, Levine MN, Hirsch J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67(6):639.
25. Kakkar VV, Murray WJG. Efficacy and safety of low molecular weight heparin (CY216) in preventing post operative venous thromboembolism. Br J Surg 1985;72:786.
26. Bergqvist D, Matzsch T, Burmark US, Frisell J, Guilbaud O, Hallbrook T, et al. Low molecular weight heparin given the evening before surgery compared with conventional low dose heparin in the prevention of thrombosis. Br J Surg 1988;75:888.
27. Leizorovicz A, Picolet H, Peyrieux JC, Borssel JP. Prevention of perioperative deep vein thrombosis in general surgery: a multicenter double-blind study comparing two doses of logiparin and standard heparin. Br J Surg 1991;78:412.
28. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988;75:128.
29. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. Comparison between low molecular weight heparin Kabi 2165 and standard heparin in the intravenous treatment of deep vein thrombosis. Thromb Haemost 1985;85:813.
30. Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, et al. Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated heparin and low molecular weight heparin. Haemostasis 1986;16(suppl):30.
31. Simonneau G. Subcutaneous fixed dose of enoxaparin versus intravenous adjusted dose of unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost 1991; 65(suppl):754.
32. Nurmohamed MT, Rosendaal FK, Buller UR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low-molecular weight heparin versus standard heparin in general and orthopaedic surgery, a metaanalysis. Lancet 1992;340:152.
33. Imperiale TF, Speroff T. Meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994;271:1780.
34. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. Br Med J 1994;309:299.
35. Lensing AW, Prins MH, Davidson BL, Hirsch J. Treatment of deep venous thrombosis with low-molecular-weight heparins: a metaanalysis. Arch Intern Med 1995;155:601.
36. Hirsch J and Levine MN. Low molecular weight heparin. Blood 1992;79(1):1-17.
37. O'Brien BJ, Anderson DR, Goeree R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Can Med Assoc J 1994;150(7):1083.
38. Occasional Life Tables, Canada and the Provinces, 1985-87 (cat no 84-532), Statistics Canada, Ottawa, 1989.
39. Canadian Hospital Indicator Data, Hospital Medical Records Institute, Toronto, 1992.
40. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KR, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424.
41. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-764.
42. Menzin J, Richner R, Huse D, Colditz GA, Oster G. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother 1994;28:271-275.
43. Teo CP, Lim HL, Kueh YK. Cost effectiveness and ease of administration of low molecular weight heparin in deep vein thrombosis. Thromb Haemost 1994;72(2):328.
44. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994;81: 1742.
45. Sifton DW, ed. Drug topics red book. Montvale, NJ: Medical Economics, 1995.